[1] Epidemic and Pandemic Preparedness and Prevention (EPP) TEAM. COVID-19 epidemiological update – 15 March 2024. https://www.who.int/publications/m/item/covid-19-epidemiological-update-15-march-2024. [2024-3-15]
[2] Eftekhari A, Alipour M, Chodari L, et al. A comprehensive review of detection methods for SARS-CoV-2. Microorganisms, 2021; 9, 232. doi:  10.3390/microorganisms9020232
[3] Gupta N, Augustine S, Narayan T, et al. Point-of-care PCR assays for COVID-19 detection. Biosensors, 2021; 11, 141. doi:  10.3390/bios11050141
[4] Luppa PB, Müller C, Schlichtiger A, et al. Point-of-care testing (POCT): current techniques and future perspectives. TrAC Trends Anal Chem, 2011; 30, 887−98. doi:  10.1016/j.trac.2011.01.019
[5] The Office of the National Health Commission, Office of the State Administration of Traditional Chinese Medicine. Diagnosis and treatment plan for novel coronavirus pneumonia (trial version 9). National Health Office Medical Letter [2022] No. 71. https://www.gov.cn/zhengce/zhengceku/2022-03/15/content_5679257.htm. [2022-03-14]. (In Chinese
[6] The State Council Responds to the Epidemic Situation of Novel Coronavirus Pneumonia, Joint Prevention and Control Mechanism Medical Treatment Team. Work manual for novel coronavirus nucleic acid testing in medical institutions (trial version 2). Joint Prevention and Control Mechanism Medical [2020] No. 313. [2020-12-28]. (In Chinese
[7] Ning PY, Yu AP, Wang Y, et al. Environmental monitoring of a laboratory for new coronavirus nucleic acid testing. Biomed Environ Sci, 2020; 33, 771−4.
[8] Taher J, Randell EW, Arnoldo S, et al. Canadian Society of Clinical Chemists (CSCC) consensus guidance for testing, selection and quality management of SARS-CoV-2 point-of-care tests. Clin Biochem, 2021; 95, 1−12. doi:  10.1016/j.clinbiochem.2021.05.010
[9] Zhang XY, He XY, Zhang YB, et al. A new method for the detection of Mycobacterium tuberculosis based on the CRISPR/Cas system. BMC Infect Dis, 2023; 23, 680. doi:  10.1186/s12879-023-08656-4
[10] Lü B, Cheng HR, Yan QF, et al. Recombinase-aid amplification: a novel technology of in vitro rapid nucleic acid amplification. Sci Sin Vitae, 2010; 40, 983−8. (In Chinese doi:  10.1360/zc2010-40-10-983
[11] Zhao KC, Cui LB, Ge YY, et al. Detection of a novel avian-origin influenza A (H7N9) virus by recombinase aided amplification. Jiangsu J Prev Med, 2016; 27, 524−30. (In Chinese
[12] Zhou DG, Luo J, Chen JH, et al. Development and application of a RT-RAA assay to detect middle east respiratory syndrome coronavirus. Chin J Virol, 2018; 34, 45−51. (In Chinese
[13] Wei Y, Guo LC, Zhang XP, et al. Establishment of Recombinase aided amplification assay for group A streptococcus pyogens detection. Chin J Frontier Health Quar, 2018; 41, 314−6,323. (In Chinese
[14] Mollaei HR, Afshar AA, Kalantar-Neyestanaki D, et al. Comparison five primer sets from different genome region of COVID-19 for detection of virus infection by conventional RT-PCR. Iran J Microbiol, 2020; 12, 185−93.
[15] Dutta NK, Mazumdar K, Gordy JT. The nucleocapsid protein of SARS-CoV-2: a target for vaccine development. J Virol, 2020; 94, e00647−20.
[16] Chinese Center for Disease Control and Prevention. Chinese Center for Disease Control and Prevention, technical guidelines for laboratory testing of novel coronavirus pneumonia. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html. (In Chinese
[17] Tang YN, Jiang DD, Wang XJ, et al. Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms. Chin Chem Lett, 2024; 35, 108688. doi:  10.1016/j.cclet.2023.108688
[18] Liang D, Wang T, Li JJ, et al. Genomic epidemiology of imported cases of COVID-19 in Guangdong province, China, October 2020 - May 2021. Biomed Environ Sci, 2022; 35, 393−401.